KLK3 and Familial prostate cancer: In the 209 patients in the control group who had an FFS event, the first reported event was PSA failure in 163 patients (78%), metastases in 33 (16%), local progression in five (2%), lymph-node progression in five (2%), and prostate-cancer-related death in three (1%).